Skip to main content
MedPathMedPath Home
Clinical Trials/JPRN-UMIN000026815
JPRN-UMIN000026815
Completed
未知

Postoperative visceral tissue edema assessed by computed tomography is a predictor of severe complications after pancreatoduodenectomy - Postoperative visceral tissue edema assessed by computed tomography after pancreatoduodenectomy

Wakayama Medical University, School of Medicine0 sites200 target enrollmentApril 1, 2017
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsDisease undergping pancreatoduodenectomy

Overview

Phase
未知
Intervention
Not specified
Conditions
Disease undergping pancreatoduodenectomy
Sponsor
Wakayama Medical University, School of Medicine
Enrollment
200
Status
Completed
Last Updated
2 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

Severe complication (Clavien-Dindo more than grade III) rate was significantly higher in Liberal fluid management(LFM) group than Goal-directed fluid management(GDFT) group (37% vs. 17%, P = 0.001).

Registry
who.int
Start Date
April 1, 2017
End Date
March 31, 2017
Last Updated
2 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
Wakayama Medical University, School of Medicine

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • •1\) Patients with combined other organs 2\) patients rejected to participate in this study

Outcomes

Primary Outcomes

Not specified

Similar Trials

Unknown
Not Applicable
Intraoperative Hyperglycemia and Infections After Orthopedic SurgerySevere HyperglycemiaPostoperative InfectionOrthopedic Patients
NCT03903354Federico Bilotta1,000
Completed
Phase 3
Study of Alvimopan for the Management of Opioid-induced Postoperative Bowel Dysfunction/Postoperative IleusIleus
NCT00205842Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)660
Completed
Phase 3
Study of Alvimopan for the Management of Opioid-induced Postoperative Bowel Dysfunction/Postoperative IleusIleus
NCT00388258Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)451
Completed
Phase 3
Study of Alvimopan for the Management of Opioid-induced Postoperative Bowel Dysfunction/ Postoperative IleusIleus
NCT00388479Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)666
Completed
Phase 3
Study of Alvimopan for the Management of Opioid-induced Postoperative Bowel Dysfunction/Postoperative IleusIleus
NCT00388401Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)510